HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

Masa Zrimsek,Kristina Draganic,Anna Malzer,Verena Doblmayr,Rafael de Freitas e Silva,Sabrina Wohlhaupter,Carlos Uziel Perez Malla,Katarina Misura,Heinz Fischer,Helga Schachner,Ana-Iris Schiefer,Raheleh Sheibani-Tezerji,Wilfried Ellmeier,Christian Seiser,Gerda Egger

DOI: https://doi.org/10.1101/2024.06.03.597085

2024-06-03

Abstract:Histone deacetylases (HDACs) play essential roles in T cell development, and several HDAC inhibitors (HDACi) have gained approval for treating peripheral T cell lymphomas. In this study, we investigated the effects of genetic or pharmacological HDAC inhibition on NPM-ALK positive anaplastic large cell lymphoma (ALCL) development to elucidate potential contraindications or indications for the use of HDACi for the treatment of this rare T-cell lymphoma. Short-term systemic pharmacological inhibition of HDACs using the class I-specific HDACi Entinostat in a premalignant ALCL mouse model postponed or even abolished lymphoma development, despite high expression of the NPM-ALK fusion oncogene. To further disentangle the effects of systemic HDAC inhibition from thymocyte intrinsic effects, conditional genetic deletions of highly homologous class I HDAC1 and HDAC2 enzymes were employed. In sharp contrast to the systemic inhibition, T cell-specific deletion of Hdac1 or Hdac2 in the ALCL mouse model significantly accelerated NPM-ALK-driven lymphomagenesis, with Hdac1 loss having a more pronounced effect. Integration of gene expression and chromatin accessibility data revealed that Hdac1 deletion selectively perturbed cell type specific transcriptional programs, crucial for T cell differentiation and signaling. Moreover, multiple oncogenic signaling pathways, including PDGFRB signaling, were highly upregulated. The accelerated lymphomagenesis primarily depended on the catalytic activity of HDAC1, as the expression of a catalytically inactive HDAC1 protein showed similar effects to the complete knockout. Our findings underscore the tumor-suppressive function of class I HDAC1 and HDAC2 in T cells during ALCL development, however systemic pharmacological inhibition of HDACs is still a valid treatment strategy, which could potentially improve current therapeutic outcomes.

Cancer Biology

What problem does this paper attempt to address?

The paper aims to explore the role of histone deacetylases (HDAC) in ALK-positive anaplastic large cell lymphoma (ALCL) and its impact on therapeutic strategies.

Specifically, researchers evaluated the effect of genetic or pharmacological inhibition of HDAC on the development of NPM-ALK-positive ALCL using a mouse model. They found that systemic use of the specific HDAC inhibitor Entinostat could delay or even prevent the occurrence of lymphoma. However, specific deletion of HDAC1 or HDAC2 in T cells significantly accelerated NPM-ALK-driven lymphoma development, with the effect being more pronounced in the absence of HDAC1.

Further integration of gene expression and chromatin accessibility data indicated that the deletion of HDAC1 specifically interferes with transcriptional programs related to T cell differentiation and signaling, leading to a high upregulation of multiple oncogenic signaling pathways. Additionally, catalytically inactive HDAC1 exhibited effects similar to complete knockout, suggesting that the tumor suppressor function of HDAC1 is primarily dependent on its catalytic activity.

In summary, the study reveals that a class of HDACs (particularly HDAC1 and HDAC2) has tumor suppressor functions in T cells, and systemic pharmacological inhibition of HDAC remains an effective therapeutic strategy that could potentially improve current treatment outcomes.